CULVER CITY, Calif. & EL SEGUNDO, Calif.–(BUSINESS WIRE)–ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that the first patient has been dosed in the Phase 1 clinical trial of hAd5-COVID-19, a novel COVID-19 vaccine candidate that targets the inner nucleocapsid (N) and the outer spike (S) protein, engineered to activate both T cells and antibodies against the coronavirus (SARS-CoV-2). This is a novel COVID vaccine that uses a second-generation adenovirus that delivers multiple proteins of the SARS-CoV-2 with the potential for long-term immunity through memory T cells. The Phase 1 trial, which is being conducted at the Hoag Hospital in Newport Beach, California, is currently enrolling healthy adult subjects up to age 55 with the goal of examining the safety and reactogenicity of two doses of the vaccine candidate.
“Our vaccine candidate, hdA5-COVID-19, targets both the nucleocapsid protein on the interior of the virus particle and the spike protein on the virus’ surface,” said Dr. Patrick Soon-Shiong, Chairman and CEO of ImmunityBio and NantKwest. “We believe this dual targeting is a key advantage that may lead to the stimulation of both T-cell-mediated and antibody-mediated immunity to SARS-CoV-2, which is an important differentiator from other vaccine candidates that only target the spike protein.”
Dr. Soon-Shiong continued, “A successful vaccine may require the stimulation of both T-cell-mediated and antibody-mediated immunity, particularly since studies have shown that patients with SARS-CoV infection have long-term T cell memory to the nucleocapsid protein. We believe that our approach, which is based on many years of experience in cancer research, could provide a robust and effective vaccine that harnesses the full potential of the immune system as an important new tool to combat the coronavirus and we look forward to advancing hAd5-COVID-19, as well as our oral, inhalational and intranasal candidates.”
About the ImmunityBio hAd5-COVID-19 Vaccine Candidate
NantKwest and ImmunityBio’s hAd5-COVID-19 vaccine candidate is a uniquely engineered, second-generation human adenovirus serotype 5 vaccine that has been designed to deliver both the spike protein and nucleocapsid protein by dual constructs of SARS-CoV-2 to potentially generate B and T cell memory to the COVID-19 antigens and long-term immunity to the virus. Most of the COVID-19 vaccines in late-stage clinical trials deliver only the monovalent spike protein on the surface of the virus to generate blocking antibodies.
Modified to enhance the safety of the vector and immunogenicity of the COVID insert, ImmunityBio’s novel human adenovirus vector has demonstrated preliminary safety in over 125 patients in 13 Phase I and 2 trials to date. Clinical studies performed by the National Cancer Institute have demonstrated that this novel Ad5 vector induces antigen-specific T-cell immunity in patients, even in the presence of pre-existing adenoviral immunity.
About the Phase I Clinical Trial
NantKwest and ImmunityBio are currently enrolling 35 healthy adults aged 18 to 55 years old in the Phase 1 study for the hAd5-COVID-19 vaccine candidate (NCT04591717). hAd5-COVID-19 will be administered as both a prime and boost using the same vector platform to enable sustained protection against SAR-CoV-2. The study’s main objective is to examine the safety and reactogenicity of two doses of the vaccine. The companies are also pursuing development for oral, inhalational, and intranasal administration of hAd5.
For more information about the trial or to enroll in it, please contact firstname.lastname@example.org.
About ImmunityBio and NantKwest Joint Collaboration Agreement
Under the terms of a definitive agreement announced on August 24, 2020, ImmunityBio, Inc. and its affiliate NantKwest, Inc. agreed to share equally the costs of development, manufacturing, marketing and commercialization of the products each is developing related to COVID-19, including the hAd5 vaccine candidate. Should a product be commercialized successfully, the companies have agreed to a 60-40 percentage split of net profits, with the larger share going to the company that developed the product. The agreement also details the structure of shared governance of the joint collaboration.
About the Hoag Center for Research and Education
The Hoag Center for Research and Education (HCRE) is a strategic and operational platform that selects, oversees and conducts government, industry, and foundation sponsored research trials translating early stage research and development into bedside patient care. HCRE’s aim is to provide the most advanced device technology, biopharmaceutical treatments, medical software and artificial intelligence health applications to the patients in our community and beyond. HCRE leadership procures, allocates and oversees the resources and regulatory requirements demanded of clinical trials, including patient safety and outcomes. Through nimble collaboration and efficient patient enrollment, HCRE conducts more than 150 trials annually. Trials span the entire spectrum of Hoag’s institute programs, including Cancer, Neurosciences, Women’s, Heart and Vascular, as well as individual investigator-initiated trials. Examples include anti-cancer vaccine therapy trials, Phase 1 cancer therapeutics, advanced cardiac and radiology interventional tools, applications of virtual and augmented reality tools for patient education and neuromodulation, cutting edge molecular imaging targets, Alzheimer’s detection and targeted biotherapeutics.
Since March, Hoag has participated in more than 20 COVID-19 clinical trials, providing patient access to cutting-edge therapies and innovative treatment including options that have documented improved outcomes, including decreased mortality and decreased length of stay for hospitalized COVID-19 patients.
ImmunityBio, Inc. is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company’s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term “immunological memory.” This novel approach is designed to eliminate the need for high-dose chemotherapy, improve upon the outcomes of current CAR T-cell therapies, and extend beyond checkpoint inhibitors.
ImmunityBio’s platform is based on the foundation of three separate modalities: antibody cytokine fusion proteins, synthetic immunomodulators, and second-generation human adenovirus (hAd5) vaccine technologies.
Anktiva™ (ImmunityBio’s lead cytokine infusion protein) is a novel interleukin-15 (IL-15) superagonist complex and has received Breakthrough Therapy and Fast Track Designations from the U.S. Food and Drug Administration (FDA) for BCG-unresponsive CIS non-muscle invasive bladder cancer (NMIBC). The company is also in Phase 2 or 3 trials for indications such as first- and second-line lung cancer, triple-negative breast cancer, metastatic pancreatic cancer, recurrent glioblastoma, and soft tissue sarcoma in combination with the company’s synthetic immune modulator (aldoxorubicin).
ImmunityBio is also developing therapies, including vaccines, for the prevention and treatment of HIV, influenza, and the coronavirus SARS-CoV-2 with its second-generation human adenovirus (hAd5) vaccine technologies.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning or implying that ImmunityBio will be successful in improving the treatment of various diseases, including, but not limited to the novel coronavirus and cancer. Risks and uncertainties related to this endeavor include, but are not limited to, the company’s beliefs regarding the success, cost, and timing of its development activities and clinical trials.
Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells—as well as their activity against a broad range of cancers—has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest’s goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies. For more information, please visit www.nantkwest.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning or implying that NantKwest will be successful in improving the treatment of cancer or other critical illnesses, including COVID-19. Risks and uncertainties related to these endeavors include, but are not limited to, obtaining FDA approval of NantKwest’s NK cells and MSC as well as other therapeutics and manufacturing challenges.
Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements.
These and other risks regarding NantKwest’s business are described in detail in its Securities and Exchange Commission filings, including in NantKwest’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.